Citi raised the firm’s price target on Ideaya Biosciences to $60 from $40 and keeps a Buy rating on the shares. While the shares have performed well, rising 26% year-to-date, the rally is not over, the analyst tells investors in a research note. The firm refreshed its model to reflect Ideaya’s “rapidly advancing pipeline,” most notably adding IDE161 in homologous recombination-deficient solid tumors to the valuation. Citi also believes the company remains an attractive takeover target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya enters supply agreement with Merck to evaluate IDE161, Keytruda
- GE upgraded, Vail Resorts downgraded: Wall Street’s top analyst calls
- Ideaya Biosciences initiated with a Buy at BTIG
- Ideaya Biosciences price target raised to $53 from $43 at RBC Capital
- Ideaya Biosciences price target raised to $50 from $40 at Oppenheimer